Several recent clinical trials have documented that vasodilators, especially angiotensin-converting enzyme (ACE) inhibitors, improve left ventricular (LV) function and increase survival in patients with chronic heart failure.12 Despite ACE inhibitors, however, many patients continue to have decreased exercise capacity and symptoms of heart failure. For those with New York Heart Association functional class IV symptoms, a recent study found a yearly mortality of 36%.3 For these reasons, there continues to be interest in the development of agents that may improve LV performance and prolong survival.
Earlier studies have suggested that there are abnormalities of intracellular cyclic AMP (cAMP) formation mance and the peripheral circulation.' Cardiac effects of thyroid hormone include increases in cardiac index, heart rate, and +dP/dt and improvement in LV relaxation.12 In addition, peripheral resistance is decreased, and changes in the venous circulation occur that promote venous return.13,14 Enhancement of myocardial contractility and relaxation by thyroid hormone and thyroid hormone analogues in papillary muscle preparations has been shown to be independent of loading conditions.15-'8 These effects on myocardial performance are thought to be initiated through binding to high-affinity nuclear receptors, which are now believed to be products of the cerb A protooncogenes.19 20 Binding to these receptors results in coordinated changes in the expression of a network of thyroid hormone-responsive genes. Among the genes affected are those encoding contractile proteins, proteins associated with amino acid and ion transport, and enzymes involved in energy metabolism. 21 The sum of these transcriptional changes is thought to provide the molecular basis for enhancement of cardiac muscle function. Thus, thyroid hormone and analogues of thyroid hormone can be viewed as regulators of genes that alter cardiac performance at the most fundamental level. Thyroid hormone itself is not useful as a pharmacological agent for the long-term treatment of heart failure, because the doses required to sustain effects on contractile performance, such as increases in the rate of pressure development (+dP/dt.mu), are associated with tachycardia.22 Also, the decrease in LV end-diastolic pressure (EDP) observed after 72 hours of treatment is not sustained with longer administration (10 to 12 days).
An analogue of thyroid hormone with low metabolic activity, 3,5-diiodothyropropionic acid (DITPA),23 recently has been shown to have relatively selective inotropic activity in hypothyroid rats.24 DITPA differs chemically from thyroxine (T4) in the absence of iodides at the 3',5' positions and in the substitution of a propionic acid side chain for the alanine side chain (Fig  1) . DITPA binds to bacterially expressed thyroid hormone nuclear receptors, induces a-myosin heavy chain mRNA expression in cultured cardiac myocytes, and produces positive inotropic activity in hypothyroid rats with less effect on heart rate than T4.24 With doses of T4 and DITPA that produced equivalent increases in +dP/ dtmax, the effects of DITPA on heart rate and hepatic a-glycerol phosphate dehydrogenase activity were about 50% less.
The purpose of the present study was to determine whether DITPA is useful for the treatment of heart failure. Rats with heart failure after ligation of the left anterior descending coronary artery were treated with captopril, the combination of DITPA and captopril, or saline (infarcted control rats) beginning 3 weeks after myocardial infarction. Earlier studies have established the value of the rat postinfarction model in the study of heart failure.2225-32 The specific question addressed was, "Does the combination of DITPA and captopril provide hemodynamic improvement over treatment with captopril alone?" At the end of treatment, several parameters of LV performance were measured, including LV pressures, cardiac output before and after volume stress, and ventricular diastolic pressure-volume relations. The results indicate that both drug regimens lowered LV EDP compared with the saline-treated control group. More importantly, the combination of DITPA and captopril improved cardiac output, increased the rate of LV relaxation, and shortened the time constant of isovolumic LV relaxation to a greater degree than captopril. Methods The animals used in this study were handled according to the animal welfare regulations of the University of Arizona and the Tucson Veterans Administration Hospital, and the protocol was approved by the animal use committees of these institutions. These regulations are in accordance with principles of animal use of the American Physiological Society and the American Heart Association.
Experimental Infarction
Myocardial infarction was produced in adult male Sprague-Dawley rats (175 to 275 g) with techniques similar to those described earlier. 26, 2830, 31 In brief, the rats were anesthetized with methoxyflurane, and a left thoracotomy was performed. The heart was expressed from the thorax, and a ligature was placed around the proximal left coronary artery. The heart was returned to the chest, and the thorax was closed. An immediate survival rate of g50% was achieved. The rats were maintained on standard rat chow (Ralston Purina Co, St Louis, Mo) with water ad libitum.
After 3 weeks, rats were anesthetized, and a nine-lead ECG with six limb leads and three chest leads was performed. Rats with evidence of large myocardial infarctions by criteria described by Pfeffer et a131 were selected for study. Briefly, the presence of Q waves >1 mV in the limb leads (I or aVL) and the sum of R waves in the precordial leads < 10 mV were used as criteria for a large myocardial infarction. Myocardial infarct size was quantified postmortem in each animal by use of techniques described earlier. 26 28 
Treatment Groups
Three weeks after infarction, age-matched rats with large infarctions by ECG criteria were randomly assigned to one of three treatment groups: (1) (Fig 2) . The Hemodynamic responses to treatments are shown in Table 2 . There were no differences in mean heart rates or in mean LV peak systolic pressures among the three groups (P>.05). Although the average maximal rate of pressure development (+dP/dtm.) was highest for the DITPA/captopril group, this value did not achieve statistical significance. Values for heart rate, LV peak systolic pressure, and LV +dP/dt were used to estimate MVo2 according to the regression equations given in 400 I "Methods" ( The average baseline cardiac index was 36% higher in the DITPA/captopril group than in the captopril treatment group (P<.05) ( Table 3) . After a 10% blood volume load, the average cardiac index was increased in all three groups. In the group treated with DITPA/ captopril, the average cardiac index was 28% higher than with captopril treatment (P<.05). Furthermore, as a result of the decrease in LV EDP and the increase in baseline and stressed cardiac indexes, the cardiac function curve for the DITPA/captopril group was shifted upward and to the left compared with both the captopril-treated group and saline-treated controls (Fig 3) . This The stroke volume index, ejection fraction index, and peak LV developed pressure were higher, and the total peripheral resistance index was lower, for the DITPA/ captopril-treated group compared with the captopril and control groups. None of these changes reached statistical significance (P>.05), however. Also, there were no significant differences in mean right atrial pressure or mean arterial pressure among the three groups ( Table 4) .
The effects of DITPA on isolated diastolic pressurevolume relations of the LV are shown in Table 5 and Fig  4. The LV volume indexes were not statistically different among the three groups at any pressure c40 mm Hg. Furthermore, there were no differences among the groups in the volume mass ratios or in K, (P>.05).
Although operating LV end-diastolic volume indexes were not different among the three groups (P>.05), the mean values for LV end-diastolic volume indexes were lower in the groups treated with captopril and DITPA/ captopril. The pressure-volume relations were similar in all groups, but treatment with captopril and DITPA/ captopril caused the hearts to operate on a lower (flatter) portion of the curve compared with the infarcted control group (Fig 5) . LV EDP was greater for the infarcted control group at LV volumes measured during both baseline and volume-stressed conditions. The operating LV end-diastolic volume indexes for these groups are shown in LV performance occurred without an increase in heart rate, which is consistent with the selective cardiotonic action of DITPA observed in hypothyroid rats.24 When DITPA was combined with captopril for the treatment of heart failure, the most desirable qualities of both DITPA (improvement in cardiac performance) and captopril (decreased preload and afterload) were evident.
Mechanisms of Increased Cardiac Output
Earlier studies have demonstrated that thyroid hormone increases cardiac output because of changes in both intrinsic myocardial properties and the peripheral circulation.1314,35 Although the combination of DITPA and captopril did not increase resting cardiac index significantly above the value in infarcted controls, in the control group this value was achieved at the expense of markedly elevated LV EDP. With the combination of DITPA and captopril, baseline and stressed cardiac indexes were improved compared with captopril treatment. The LV EDP was decreased, and there were only minor changes in peripheral resistance. Thus, the upward and leftward shift of the cardiac function curve suggests that enhanced myocardial performance was partly responsible for the improvement in cardiac output.
Abnormalities in LV diastolic function are frequently present in the failing left ventricle and in some cases may supersede systolic dysfunction as the predominant cause of congestive symptoms.36 In the present study, improvement in diastolic function, as reflected in changes in -dP/dtmax and r, may have contributed to the increase in cardiac index and lower LV EDP observed with DITPA treatment. Whereas captopril tended to prolong relaxation, the addition of DITPA facilitated (shortened) relaxation. Since no differences were observed with respect to ex vivo pressure-volume relations, the improvement in relaxation and cardiac index probably was not the result of changes in the passive elastic properties of the ventricle but rather of alterations in active, energy-dependent relaxation.
Effects of DITPA on the peripheral circulation undoubtedly contributed to the increase in cardiac index. Thyroid hormone is known to decrease systemic vascular resistance and venous compliance while increasing mean circulatory filling pressure and the pressure gradient for venous return (the gradient from peripheral veins to right atrium).12-'4 Both experimental and theoretical results suggest that the decrease in arterial resistance probably does not play as large a role in increasing cardiac output in hyperthyroidism as once was supposed. For example, raising the peripheral resistance to the euthyroid level with phenylephrine decreases cardiac output by only a small percent.'3 The failing heart is more dependent on afterload than normal,37 however, and it is conceivable that the tendency of DITPA to reduce peripheral resistance may have contributed to the afterload-reducing effect of captopril in the infarcted animals. Thus, the increase in cardiac index observed with DITPA is likely to The explanation for the lack of effect of DITPA on heart rate compared with the marked positive chronotropic effect observed with L-thyroxine remains unknown. Competition binding studies with ['lI]triiodothyronine indicate that DITPA binds with similar affinities to the a1-and 81-subtypes of the thyroid hormone nuclear receptor.24 Possibly, the more lipophilic character of DITPA may alter its distribution within the heart and other tissues.
Limitations
In this study, DITPA was used as adjuvant treatment to captopril, precluding any direct comparisons between DITPA and captopril as single agents. This study design is justified and clinically relevant because ACE inhibition is currently the most effective medical treatment for heart failure after myocardial infarction. The beneficial effects in the DITPA/captopril group are not likely to be related solely to captopril, however, because earlier work has demonstrated minimal direct effects of captopril on contractile performance in papillary muscles of animals given a similar course of treatment. 55 Although the results demonstrate improvements in LV performance with DITPA/captopril treatment, it remains to be established whether this hemodynamic benefit will translate into improved survival with heart failure after myocardial infarction. Earlier studies have shown that cardioactive agents can both improve hemodynamics and prolong survival, however, suggesting that these two end points are not mutually exclusive.1"56 Also, it is well established that activation of the renin-angiotensin system and other neurohormonal pathways is an important consideration in the treatment of heart failure, but the effects of DITPA on these pathways is beyond the scope of the present study.
Since MVo2 was not measured directly, it is possible that DITPA may increase energy utilization by processes that are not reflected in mechanical measures of LV performance. Previous studies have demonstrated that MVo2 in experimental hyperthyroidism correlates well with the maximum rate of tension development in papillary muscles, however, with increased basal metabolism accounting for no more than 10% to 11% of the increase in energy demand.57 Although it is conceivable that uncoupling of oxidative phosphorylation may have occurred with DITPA treatment, this phenomenon has been described only at extremely high doses of T4 (4 to 8 mg per day),58'59 which would be equivalent to approximately a 500-fold greater dose of DITPA than was administered.
Conclusions
This study demonstrates improvement in LV function with the addition of DITPA, a thyroid hormone analogue, to captopril treatment in rats with infarct-induced heart failure. DITPA improves cardiac performance by a combination of actions, including effects on the heart and peripheral circulation, that are thought to be mediated by binding to high-affinity nuclear receptors and alterations in gene transcription. Currently, none of the agents used for the treatment of heart failure regulate gene transcription or alter protein synthesis within the intracellular milieu of the failing myocardium. Because of this unique mechanism of action, DITPA and perhaps other thyroid hormone analogues offer hypothetical advantages over current inotropic agents by promoting the coordinated synthesis of myocardial proteins involved in intracellular Ca 2 movement and the excitation-contraction coupling process.
